Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

BACKGROUND: Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequate...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3606470/
https://ncbi.nlm.nih.gov/pubmed/23425012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-11-43
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki